Comparison side by side between the following: LivaNova PLC (LIVN) and Cesca Therapeutics Inc. (NASDAQ: KOOL).

Cesca Therapeutics Inc. beats 5 out of 8 variables against LivaNova PLC.
LivaNova PLC, a manufacturer of medical devices, designed, developed, fabricated and sold globally therapeutic alternatives. It works in three sections: Neuromodulation, Cardiac Surgery, and Management of Cardiac Rhythm. The segment Neuromodulation designs, creates and markets the therapeutic system for vagus nerve stimulation (VNS), an implantable device for the treatment of drug-resistant epilepsy and therapy-proof anxiety, and develops transcutaneous VNS equipment. The segment provides neurologists, neurochirurgas, ENT surgeons, hospitals, and healthcare systems.
The Cardiac Surgery segment designs manufacture and sell cardiovascular surgery goods including oxygenators, cardiovascular machinery, perfusion tubes, cannulas and accessories, autologous blood automatic transfusion devices, tissue surgery, and valve replacement and cardiovascular repair products, mainly for perfuse and infusion surgeons, for damaged or diseased heart valves. The Cardiac Rhythm Management segment develops, produces, and markets products in which heart rhythm disorders and insufficiency can be diagnosed, treated and managed.
This section provides implantable heart pacemakers, cardioverter defibrillators, cardiac resynchronization and instruments for patient treatment, mainly for electrophysiologists, cardiologists and cardiac insufficiency experts. VITARIA systems for heart failure therapy are also developed in this section. The business sells its goods via direct sales agents and autonomous dealers. It has its headquarters in London, United Kingdom and was established in 1987.
Cesca Therapeutics Inc. focuses on research, development, and marketing of autologous cell-based therapeutics in the United States and internationally for the use in regenerative medicine. The firm designs and manufactures automated handling systems for blood and bone marrow that allow cell and tissue treatment products to be separated, processed and maintained.
Its goods include the SurgWerks scheme, a proprietary scheme consisting of a SurgWerks platform for processing instruments and analysis and an indication-specific SurgWerks procedures kit for the use in the treatment of vascular and orthopedic illnesses in regenerative stem cell therapy.
The Company provides MarrowXpress scheme, a derivative product of AXP for insulation and concentrating hematopoietic stem cell products of the bone marrow, BioArchive scheme, an automated cryogenic device used in the cryopreservation and storage of cord-blood stem cell concentrates by cord-based blood banks for future use, and manual disposable bag sets. It also offers cell production and banking services.